Resultados de la búsqueda 331-340 of 5144 for sids
Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in ...
Rochester, Minn. The natural course of autosomal dominant polycystic kidney disease (ADPKD) is highly variable and typically characterized by progressive ...
After enrollment, patients will receive one cycle of Induction chemotherapy. Subsequent therapy will be based upon MIBG avidity and ALK status. Patients with ...
Collection of tissue and blood from patients with residual disease after neoadjuvant systemic therapy for breast cancer. We hope to use these samples to ...
Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
This randomized phase III trial compares memantine hydrochloride and whole-brain radiotherapy with or without hippocampal avoidance in reducing neurocognitive ...
The primary purpose of this study is to assess the feasibility of performing lung and kidney and lung ultrasound elastography among patients with critical ...
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...
This study aims to demonstrate acceptability and feasibility of the use of Distance Reiki therapy versus sham Reiki therapy among multiple myeloma patients.
Establish a prospective database of all patients with peritoneal surface malignancies seen by Dr. Travis Grotz at the Mayo Clinic, Rochester. Design and ...
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?